ࡱ> sRoot Entry@N3__properties_version1.00U__nameid_version1.0(`P0J@N__substg1.0_0E04001F*8$  r"#$%&'()*+,-./0123456789:;<=>?@ABCDEFHIJKLMNOPQRSTUVWXYZ[\^_`abcdefghijklmnopquvwxyz{|}~Root Entry Ff3__properties_version1.00U__nameid_version1.0(`P0J@N__substg1.0_0E04001F*8$  r"#$%&'()*+,-./0123456789:;<=>?@ABCDEFHIJKLMNOPQRSTUVWXYZ[\^_`abcdefghijklmnopquvwxyz{|}~__substg1.0_0E03001F* __substg1.0_0E02001F*__substg1.0_001A001F*T__substg1.0_002C0102*7S<__substg1.0_003B0102* R__substg1.0_003F0102*9O__substg1.0_0040001F* N"__substg1.0_00410102*Ln__substg1.0_0042001F*K __substg1.0_00430102*H__substg1.0_0044001F* G"__substg1.0_00510102*Em__substg1.0_00520102*Cm__substg1.0_0064001F*B__substg1.0_0065001F*A(__substg1.0_0070001F*j__substg1.0_00710102* $@__substg1.0_0075001F*?__substg1.0_0076001F*;__substg1.0_0077001F*:__substg1.0_0078001F*6__substg1.0_007D001F*t8/__substg1.0_0C190102*4n__substg1.0_0C1A001F*3 __substg1.0_0C1D0102*2__substg1.0_0C1E001F*1__substg1.0_0C1F001F*0(__substg1.0_0E9D0102*/__substg1.0_1000001F*"]2(__substg1.0_10090102*G*__substg1.0_10130102*!#!FK__substg1.0_1015001F*-r__substg1.0_1035001F*,+b__substg1.0_1039001F*)t__substg1.0_1042001F*%''t__substg1.0_300B0102*&__substg1.0_30140102*&*% __substg1.0_3FF8001F*$"__substg1.0_3FF90102*)+!__substg1.0_3FFA001F* __substg1.0_3FFB0102*(0n__substg1.0_4030001F*(__substg1.0_4031001F*-/(__substg1.0_5D01001F*(__substg1.0_5D02001F*.4(__substg1.0_65E00102*__substg1.0_65E20102*13__substg1.0_65E30102*__substg1.0_8001001F*26__substg1.0_8002001F*(__substg1.0_8003001F*5:B__substg1.0_0037001F* t__substg1.0_0E1D001F*j__substg1.0_003D001F* __recip_version1.0_#00000000:>;W@N@N__attach_version1.0_#00000000<<L@N@N__attach_version1.0_#00000001<C@N@N__substg1.0_8006001F* F__substg1.0_8007001F*=&__properties_version1.00xH "#(*,.5789<=>DFIJMPQVWXYZ[\]^_`abcdefghijkouyz{|}RE: IRAS 183040. Confirmation of Amendment AssessmentRE: IRAS 183040. Confirmation of Amendment AssessmentPakats, Mari-Liis00000003rl1vmcas01.live.trust.xblt.nhs.uk/o=NHS NTHAMES HN/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=Pakats Mari-Liis0b0Mari-Liis.Pakats@bartshealth.nhs.ukFwd: Fwd: RE: IRAS 183040. Confirmation of Amendment AssessmentRL1VMEXC02.live.TRUST.XBLT.NHS.U__substg1.0_0FF90102*w__substg1.0_3001001F*@Bv__substg1.0_37010102*tv__substg1.0_3703001F*AEs__substg1.0_3704001F*r__substg1.0_3707001F*DGq__substg1.0_370E001F*p__substg1.0_3712001F*F?n^__properties_version1.00H__substg1.0_0FF90102*__substg1.0_3001001F*IK__substg1.0_37010102*__substg1.0_3703001F*JN__substg1.0_3704001F*__substg1.0_3707001F*MP__substg1.0_370E001F*__substg1.0_3712001F*OH~^__properties_version1.00(__substg1.0_3001001F*"__substg1.0_3002001F*VT__substg1.0_3003001F*__substg1.0_0FF60102*__substg1.0_0FFF0102*UR__substg1.0_300B0102*SYm__substg1.0_3A20001F*Z["__substg1.0_5FF70102*XQ__substg1.0_39FE001F*F__substg1.0_5FE5001F*KBT=2;II=<invalid>;SBMID=109;SBT=314;S2=<f9647316f7ca6259ba0bbb4a40302609@prismtrial.org>;FIXUP=426.0274;Version=Version 14.3 (Build 312.0), Stage=H6Anonymous7**FJfJe7**FJfJe7**FJfIadmin@prismtrial.orgadmin@prismtrial.orgadmin@prismtrial.orgadmin@prismtrial.org+nTPRISM Trial TeamSMTPadmin@prismtrial.orgPRISM Trial Teamܧ@B+//O=NHS NTHAMES HN/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=PAKATS MARI-LIIS0B0Pakats, Mari-LiisGBW&iGI䥉G<780c5c1ea70b48e49ff1ca7f9068761a@NH-SLPEX113.AD1.NHS.NET><780c5c1ea70b48e49ff1ca7f9068761a@NH-SLPEX113.AD1.NHS.NET><c4cb2244fdfcc72e858c011a3184aeb5@prismtrial.org>52D46EDB9E4C4A478CD694CABE4CF5F3@bartsandthelondon.nhs.ukSophos
Subject: RE: IRAS 183040. Confirmation of Amendment Assessment
Date: 19/06/2017 15:44
From: "TOTENHOFER, Ashley (HEALTH RESEARCH AUTHORITY)" <ashley.totenhofer@nhs.net>
To: "admin@prismtrial.org" <admin@prismtrial.org>
Cc: "r.pearse@qmul.ac.uk" <r.pearse@qmul.ac.uk>, "spnsorsrep@bartshealth.nhs.uk" <spnsorsrep@bartshealth.nhs.uk>, "t.abbott@qmul.ac.uk" <t.abbott@qmul.ac.uk>


Dear Mari-Liis

 

Further to the below, I am pleased to confirm that HRA Approval has been issued for the referenced amendment, following assessment against the HRA criteria and standards.

 

The sponsor should now work collaboratively with participating NHS organisations in England to implement the amendment as per the below categorisation information.  This email may be provided by the sponsor to participating organisations in England to evidence that the amendment has HRA Approval.

 

Please contact hra.amendments@nhs.net for any queries relating to the assessment of this amendment.

 

Kind regards

 

Ashley

 

 

cid:image003.jpg@01D0D365.7F1F4DE0

Dr Ashley Totenhofer | Technical Assurance Officer
HRA Centre Manchester

3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ
E: ashley.totenhofer@nhs.net | T: 0207 104 8017
www.hra.nhs.uk

 

Would you like to receive the latest updates on HRA work? Sign up here

 

For more information on the HRA Approval process Click here


The HRA is keen to know your views on the service you received – our short feedback form is available here

 

 

From: NRESCommittee.London-Central@nhs.net [mailto:NRESCommittee.London-Central@nhs.net]
Sent: 04 May 2017 08:48
To: admin@prismtrial.org
Cc: r.pearse@qmul.ac.uk; spnsorsrep@bartshealth.nhs.uk; t.abbott@qmul.ac.uk
Subject: IRAS 183040. Confirmation of REC Validation and Categorisation of Amendment

 

Dear Professor Pearse,

IRAS Project ID:

183040

REC Reference:

15/LO/1595

Short Study Title:

PRISM

Date complete amendment submission received:

25 May 2017

Amendment No./ Sponsor Ref:

2

Amendment Date:

13 April 2017

Amendment Type:

Substantial

Thank you for submitting the above referenced amendment. I am pleased to confirm that this amendment has been submitted to the REC for ethical review. Please find attached a copy of the validation letter.

Categorisation of Amendment

In line with the UK Process for Handling UK Study Amendments I can confirm that this amendment has been categorised as:

Category C - An amendment that has no implications that require management or oversight by the participating NHS organisations

As such, the sponsor may implement this amendment as soon as any relevant regulatory approvals are in place (for participating organisations in England, this includes receiving confirmation of HRA Approval for the amendment).

As Chief Investigator/Sponsor, it remains your responsibility to ensure that the research management offices and local research teams (if applicable) at each of your participating organisations are informed of this amendment.

Note: you may only implement changes described in the amendment notice or letter.

Please do not hesitate to contact me if you require further information.

Kind regards

Julie Acourt

REC Assistant

Health Research Authority

HRA, Ground Floor, Skipton House, 80 London Road, London, SE1 6LH

E: hra.amendments@nhs.net


www.hra.nhs.uk


The HRA is keen to know your views on the service you received – our short feedback form is available here

 



********************************************************************************************************************

This message may contain confidential information. If you are not the intended recipient please inform the
sender that you have received the message in error before deleting it.
Please do not disclose, copy or distribute information in this e-mail or take any action in reliance on its contents:
to do so is strictly prohibited and may be unlawful.

Thank you for your co-operation.

NHSmail is the secure email and directory service available for all NHS staff in England and Scotland
NHSmail is approved for exchanging patient data and other sensitive information with NHSmail and other accredited email services.
NHSmail provides an email address for your career in the NHS and can be accessed anywhere
For more information and to find out how you can switch, visit http://support.nhs.net/joiningnhsmail

********************************************************************************************************************

*LZFu rcpg1252Chtml11bid0 'ch set0 PVUUQW2U3FYkcm ;O05R `cgP d36 4r *\9 <>cg3 ead} 4oh}_lmnoqrϕߜ_v_woxy>=To{|ߕ?_/ߊJ y @pJН1.g߯ύ߱_?/Oϙߚ?O_o>=Cc_?occr.p#@qmu.uk׿ϴoO'Pܯ',sPp@0 #h0ݟޯ߿_oO_otb@oߎ9_/o?wHЂ3 / ;+[ p.w1+qb\r8/0$!-- b ,ed #x#O _ I+!"#O_+S. v,/J0W,S?aIq1ͼ',)MvN&I@l+?,O@AB/C?DOE_FoO/HIJKLM`{R~uXP P0 .b``Im >pARifnfi_iat HRA`ppo˱!`@iᏀQ*0uQdPiaicQd۸ tdPlj@>g@*0oga@bil2cp߸o`br]pd PQ/8 00cmJ @pߤ_o}e~愐-50%€~A_m}U34 ?o)42.2 oo Ԙ#ϲBZDE/)pgb?{ufo/?O_y4e28c05?ȿ/ɯʲ"xPy$@tipy`Pp@?O|&nb;oy'a?O_o݋zOݛĎ䏤ϧ߮_A?O_Eo_oO_oΏ WV yV k)PR#pv`*! P^d2)"w`k?W1O  Co@i /y/O/|_/}s8.PnnQmSذcA be?u=mak0e0#f38e`b355& Pid=1a71Ҁ9a ~o/: <o O*Tp2O_0o1?4*,673/@?O_oPrg^йT÷?RABYD?EOF_GoHIJKL4Xdk?STUV /jnF[М0[[np ArBAppl xM@_O`_mzO{_op/q?rOs_toy}o~W#wR.0a.$k6b_P/r-pdlrj ts6M@xmPaw/!"#-ϖ()?,/.?Cck0a/?O6o?Ϥ/?OZ?[Oboc?efghϺOlm{ oI6ڀ\_o?|}O_oޏߟTwu$ P`"Zk`w@vweà^`9rshppfdb vRax0Лo/ߌ߿?wϚovgx P%n`/qu!0 /? / 4/?/?O//_"o!$(+?s1À1Ag g0EN-US.?o&'$<>OƏǟȯ/ɿ8v8FqtdFGF5*IJ08I@ dyL/M?NG"AE?OHSJKVMOYQ/R?SO\/i7?./13?c89[&nbe;y'a0k:^BOC_DoEF`abkdfgh/i?jO|lomnopqrstuxy/ v rd`𻘴`o P iP#B5C4DF0dd g`3b 0c?Oz{})*}~̀0o2QTappOTFm:@ NRESCP2 0.Lrd-C2@w[p2 :]/?SQo{`May 20178:U/?O_o TƏǛ#2n@p2sm͐2. gʏ˟̯Ϳ CcϟЯnjr.p5@e@qm-.AP` s0p@`[5@htb 0yzubjP_}I0S083[O `tio0C VdpP``AmҠQ:/ϐߞ]O_oo_񏈏 ߿12_D! Pfe#, o <^Ck ^a"<-p`)P1(lce)Qc0+,R{%d% !p/s$&[o0X#/4 UUw߀A`262.5k.~7:;(:35-}6o7UorO>?!D/ODT o!"#3/@nNPAq/9`Z[{K?Y9;<K/`@Y@ABCDEFGIJem$MNOPQRST|?WX/yZO[_\o]?5r?O5?e?a_9:c<=O_hjnl/m?nO?o_poqrRePvn+Muwxy/z?{O|_o~/τ^_ύbdߵ_fhߖ/?O_oAs5/LO/@95?O_o/Ϭo//_/?՟?o_o߾o/?Og_o;ShːM0Stu2 Tit@//?Oo֟ؿ/?o培 /?O_|PRISMo&#O/?O_-/?/* oo 4?5O6_/?=O_o=Date@PompF KAGdLsubH@iB iv _ !"$%&/U(O)_R_+1-._ oY7_ :a?@ABCDFGH/I?e25 Ma2017MNPQR/S?TOU_|WXz/Z[\]߃0߆24_>a8O9_d;/?ijkl/noprsMAL./0pǙRefMvwxyz{}/?/_߄^_O?c_e?g_hoϛߜtϥߦ/O__Oߊ֏_/?_O_o_o_įſ?LDK"/?__o׏ٯڿo揻 O/?O/?O<13plu_?"O?&oo-ܟ0/1?O_ ?O6?7O>Typ "#$/%?&O(T)*Q,3/./  >8 O;o`o@ABDEF/G?HOI_JgiolOaqbluedmeSubo0otqM_NoOPQRST}/VWzoZ[/\?]O/2_80vхbodyϊaspe|oό4ǃ1smnoOpqsϓdThk yousu@-0tul :e َPovwfcw U. I!o:ЕPiwtw@snPCcacrpyw0v9il Pruvxy~O_o//?OklϘCgПЦDLgo{_/?O_Ķ/?_ooYIc9:hڰ`tp:(//w.a.nhs.uk/dHocus/4"/ۀ/gu9e-o͐ݰrݐ`-_p ݐadgk`u-7@pdf,eldRfc`{HYPERLINK /?O_o"}^4\cf1\^uo?`UPH aSBLXsϟ}a0ѣ@sܰ/?_o׏O |`C?oG~AxӠ@m0RP`q` jpneLA 0s`` uci NHS&1gоUP/? O _1/O_o KP0,7$jp`#%-6 6u;68 :;$=pq%!i0>"ibo`p'!`Л0%a՜b$%f!L!`lwo@P(pM$"a)qruW(NT`J^_`abcdfgh/i?jO@Aolmnopߐ7NozpS󌗿U/?O_u>>`%PZcPPpN]#']]0 φ߇/?/*Pp#]쀨#pvvBQc& |c%fu0]0~\ϭ߮/?Oɏo{zK M0d)o/?O_ȍ͟ϿAyrp{NkOUJEPr`P/?O_oueO?O܏ݟޯ߿?/OlREC=1`L_o /U60{[M@ MKP[tlT{r"'PZrM0#[ ll dd[a#K dM@Ya\&Pspo ~#0dy(tO'?1+O+148!A$%.751#N!vPp?-.50qp!4!O_o4_m345p<[id:hra-ytgo#sw:?$bATT-1-{ykp.g> }#=Pt:\LAwA@]:6#] 0E#8*=@A} d:0P98045783@594a5dJ2 31667170`8810@]m=A.XDOE_FoH\objwtpw&/?LVQ/*\S00q/0\]>[0_1o2}>b6WWo[[ۏGYj(!o"#$%&`m/)t,g_hox/cefyz{789:;<pỀ%H\@QR`罐B0QAuTyRoSTUWoXYZ[w/_/oyyO|}~o߃/?OoeM, GrF0Ski@?=0JMുRoq0TE1 6LH_o߼/ϖߗo/?_ooO/?O_oEOaNfo`3:I!.٠epAts@nhs.net\f`ldBf`Pנ{HYPERLINK M}ars\cf1\@so?a O?O_ğƿܿҟ/?Oԏ՟֯׿gK bZ\3_ oK/3w.uk_o/&'/_)_/,o/0  / ? O _o=P :g5/w@6,TOs ke pEXw yp7v@wEnpGpF& 0pivA\'[mFs3@fEdpback_`:S&nb:;By'a0def߇Oh//2voABo:5wKJaPpGHCHHG{[rpP@q 0;0`20t.׽D\Pd 2U2sPo>P,!p϶@Q{pibU6’GJU2EKn@J`˖`VGRPEb:oƏD\F18Eʒ͠=0`bP:Љ"0 unK`wf_?O_D|:JHRJF0-[/?_oDNHS̃JGcIGẽ2HF0r@GK(¡Ag@:afжE2K`S0џ/?O_fap!Hexc1gP`dLҹ@[G> PHwPhbJ`cՃGŨb!K±28޹Gr`:Qգyw[D\Fmb*F1R@ULFs0GaL?TPPIs`t/jo22T̂O_o _/?O/?Obdo/?_o5wx~Oq7%#2%3&}+Subject: RE: IRAS 183040. Confirmation of Amendment Assessment Date: 19/06/2017 15:44 From: "TOTENHOFER, Ashley (HEALTH RESEARCH AUTHORITY)" <ashley.totenhofer@nhs.net> To: "admin@prismtrial.org" <admin@prismtrial.org> Cc: "r.pearse@qmul.ac.uk" <r.pearse@qmul.ac.uk>, "spnsorsrep@bartshealth.nhs.uk" <spnsorsrep@bartshealth.nhs.uk>, "t.abbott@qmul.ac.uk" <t.abbott@qmul.ac.uk> Dear Mari-Liis Further to the below, I am pleased to confirm that HRA Approval has been issued for the referenced amendment, following assessment against the HRA criteria and standards. The sponsor should now work collaboratively with participating NHS organisations in England to implement the amendment as per the below categorisation information. This email may be provided by the sponsor to participating organisations in England to evidence that the amendment has HRA Approval. Please contact hra.amendments@nhs.net for any queries relating to the assessment of this amendment. Kind regards Ashley Dr Ashley Totenhofer | Technical Assurance Officer HRA Centre Manchester 3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ E: ashley.totenhofer@nhs.net | T: 0207 104 8017 www.hra.nhs.uk <http://www.hra.nhs.uk/> Would you like to receive the latest updates on HRA work? Sign up here <http://nhs.us8.list-manage2.com/subscribe?u=04af4dde330becaf38e8eb355&id=1a71ed9a1e> For more information on the HRA Approval process Click here <http://www.hra.nhs.uk/about-the-hra/our-plans-and-projects/assessment-approval/> The HRA is keen to know your views on the service you received  our short feedback form is available here <http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/> From: NRESCommittee.London-Central@nhs.net [mailto:NRESCommittee.London-Central@nhs.net] Sent: 04 May 2017 08:48 To: admin@prismtrial.org Cc: r.pearse@qmul.ac.uk; spnsorsrep@bartshealth.nhs.uk; t.abbott@qmul.ac.uk Subject: IRAS 183040. Confirmation of REC Validation and Categorisation of Amendment Dear Professor Pearse, IRAS Project ID: 183040 REC Reference: 15/LO/1595 Short Study Title: PRISM Date complete amendment submission received: 25 May 2017 Amendment No./ Sponsor Ref: 2 Amendment Date: 13 April 2017 Amendment Type: Substantial Thank you for submitting the above referenced amendment. I am pleased to confirm that this amendment has been submitted to the REC for ethical review. Please find attached a copy of the validation letter. Categorisation of Amendment In line with the UK Process for Handling UK Study Amendments <http://www.hra.nhs.uk/documents/2014/11/guide-researchers-uk-process-handling-uk-study-amendments.pdf> I can confirm that this amendment has been categorised as: Category C - An amendment that has no implications that require management or oversight by the participating NHS organisations As such, the sponsor may implement this amendment as soon as any relevant regulatory approvals are in place (for participating organisations in England, this includes receiving confirmation of HRA Approval for the amendment). As Chief Investigator/Sponsor, it remains your responsibility to ensure that the research management offices and local research teams (if applicable) at each of your participating organisations are informed of this amendment. Note: you may only implement changes described in the amendment notice or letter. Please do not hesitate to contact me if you require further information. Kind regards Julie Acourt REC Assistant Health Research Authority HRA, Ground Floor, Skipton House, 80 London Road, London, SE1 6LH E: hra.amendments@nhs.net www.hra.nhs.uk The HRA is keen to know your views on the service you received  our short feedback form is available here <http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/> ******************************************************************************************************************** This message may contain confidential information. If you are not the intended recipient please inform the sender that you have received the message in error before deleting it. Please do not disclose, copy or distribute information in this e-mail or take any action in reliance on its contents: to do so is strictly prohibited and may be unlawful. Thank you for your co-operation. NHSmail is the secure email and directory service available for all NHS staff in England and Scotland NHSmail is approved for exchanging patient data and other sensitive information with NHSmail and other accredited email services. NHSmail provides an email address for your career in the NHS and can be accessed anywhere For more information and to find out how you can switch, visit http://support.nhs.net/joiningnhsmail ******************************************************************************************************************** admin@prismtrial.orgSMTPSMTP:ADMIN@PRISMTRIAL.ORGPRISM Trial Team+nTPRISM Trial TeamSMTPadmin@prismtrial.org/O=NHS NTHAMES HN/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPReceived: from SB1VASOP03.live.trust.xblt.nhs.uk (10.117.246.170) by RL1VMEXC02.live.trust.xblt.nhs.uk (10.117.247.55) with Microsoft SMTP Server (TLS) id 14.3.319.2; Wed, 21 Jun 2017 12:49:52 +0100 Received: from SB1VASOP03.live.trust.xblt.nhs.uk (localhost.localdomain [127.0.0.1]) by localhost (Email Security Appliance) with SMTP id 382501FD20D_94A5D60B for <mari-liis.pakats@bartshealth.nhs.uk>; Wed, 21 Jun 2017 11:49:52 +0000 (GMT) Received: from smtp1.e.amses.net (unknown [155.231.210.221]) (using TLSv1.2 with cipher ECDHE-RSA-AES256-GCM-SHA384 (256/256 bits)) (Client CN "IMSVA.TREND", Issuer "IMSVA.TREND" (not verified)) by SB1VASOP03.live.trust.xblt.nhs.uk (Sophos Email Appliance) with ESMTPS id 5BB2F1FA4EF_94A5D5BF for <mari-liis.pakats@bartshealth.nhs.uk>; Wed, 21 Jun 2017 11:49:47 +0000 (GMT) Received: from smtp1.e.amses.net (OP-SLPIMS05.ops.amses.net [127.0.0.1]) by IMSVA (Postfix) with ESMTP id 422B43589EF for <mari-liis.pakats@bartshealth.nhs.uk>; Wed, 21 Jun 2017 12:49:45 +0100 (BST) Received: from Prefilter-postMTA15.emailsecurity.trendmicro.eu (prefilter-postmta15.emailsecurity.trendmicro.eu [150.70.236.151]) by smtp1.e.amses.net (Postfix) with ESMTPS id 2F08635898C for <mari-liis.pakats@bartshealth.nhs.uk>; Wed, 21 Jun 2017 12:49:45 +0100 (BST) Received: from hes.trendmicro.com (unknown [10.36.141.133]) by Prefilter-postMTA15.emailsecurity.trendmicro.eu (Postfix) with SMTP id 93FCFB00073 for <mari-liis.pakats@bartshealth.nhs.uk>; Wed, 21 Jun 2017 11:49:46 +0000 (UTC) Received: from dedivps-30230.dedicloud.co.uk (unknown [149.255.61.21]) by prefilter-premta5.muc1 (Postfix) with ESMTPS id B820A680038 for <mari-liis.pakats@bartshealth.nhs.uk>; Wed, 21 Jun 2017 11:49:43 +0000 (UTC) Received: from webmail.prismtrial.org (localhost [IPv6:::1]) by dedivps-30230.dedicloud.co.uk (Postfix) with ESMTPA id 2D50514BA1EA for <mari-liis.pakats@bartshealth.nhs.uk>; Wed, 21 Jun 2017 12:49:43 +0100 (BST) MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="=_fc130b5e66a8083fbf79cdb1173a4089" Date: Wed, 21 Jun 2017 12:49:43 +0100 From: PRISM Trial Team <admin@prismtrial.org> To: Mari-liis Pakats <mari-liis.pakats@bartshealth.nhs.uk> Subject: Fwd: RE: IRAS 183040. Confirmation of Amendment Assessment In-Reply-To: <780c5c1ea70b48e49ff1ca7f9068761a@NH-SLPEX113.AD1.NHS.NET> References: <780c5c1ea70b48e49ff1ca7f9068761a@NH-SLPEX113.AD1.NHS.NET> Message-ID: <c4cb2244fdfcc72e858c011a3184aeb5@prismtrial.org> X-Sender: admin@prismtrial.org User-Agent: Roundcube Webmail/1.2.4 X-TM-AS-GCONF: 00 X-TM-AS-Product-Ver: IMSVA-9.0.0.1623-8.1.0.1062-23146.006 X-TM-AS-Result: No--17.258-5.0-31-10 X-imss-scan-details: No--17.258-5.0-31-10;No--17.258-3.0-31-10 X-TMASE-Version: IMSVA-9.0.0.1623-8.1.1062-23146.006 X-TMASE-Result: 10--17.257500-10.000000 X-TMASE-MatchedRID: OoEa6u7Uk5/xbSCwUpzgngdVB7UxMI/EtXl9IxEPXOpn9ZawlOQwayXe raYN3tiO0gd0/rtgz+fsj9OIws4VKOLdprnA5EQRZodCyXXZLezkMnUVL5d0E9jI3XkSN9ENLr8 WwYKv6dz2EY6UlCIXii4kKugRogg4bvssW25GCBYZbpN+hw0Ke2NDqjXOO0YeaF29jZP2X5dmFh yCFuJbaWyGQpsiPfAipCUIBgb5OwmBYaYUZf0IFYRhNlXHOosXsneuamRRT5N8f/TvbwD71Pn+r UojgHnzbCALK/ujtqeGtnaR4Gvlr5mug812qIbzO1K5iM8Q6KC67Q3uPo9KI+KfVRMbjCR2RJmB h7Wt+jawcLl0FTRX98vRJN+hUTd8zh9nd7xTXgrSv+oK79xjnfxsP7g8BleLdH4rpcW6mBCw3wt l04XimGq9vypzp4UBGvea2qfHikYshGpBsK6H7kH7wsB5444wCf9uyputvwWhlyriI92uZe/ohV +tou5Tfo01VKqUOeqHOxfv+9io8DiU1nXLlwv+hiz2Z8FMsb3JwfJEFqACwVUvFaU/yUB23yyt/ /voBWNJx5vUf5xUCh6mfPZJOjt0mAafP3c9X3fkEInkbDqFCrVgSYnadOqypq+UjBHr/zfIcacg mxorj9RkgfXwQXSRFS1+qCxplouq8RUDM9IsXA3mvPKZj/z++g9MLnUuyPEIZJR7eWK/XCqbhLk g12MX4YS6FyG8vyjyUQNiagGSs9sfxZpQv2qM/AZW18vjv1oUtdRZTmEaIdvL8kSKQfWEoyLcEl 25bYFM57qX4AqdfVR3DUuqYpe9FQoOTNWynxVkMOQFVEfPHdMMeoqMaA2rrcmmD7/hK1/gT2zXY a9/nVwtzewu2M6371zr0FZRMbBCxGiZ1+iJr+DcbUU3B14wRXjI9mRD4z6W8+O8y93Tc0S80iGH S+DSF2Yu18NCXb2alwdnnQJ9pn7cGd19dSFd X-TMASE-SNAP-Result: 1.821001.0001-0-2-12:0,17:0,22:0,33:0,34:1,35:0,36:0,37:0,39:0,40:0-0 X-Sophos-SenderHistory: ip=150.70.236.151,fs=5484530,da=55039724,mc=236115,sc=3371,hc=232744,sp=1,fso=46142109,re=36,sd=1,hd=28 X-Sophos-ESA: [SB1VASOP03.live.trust.xblt.nhs.uk] 4.2.1.0, Antispam-Engine: 2.7.2.2107409, Antispam-Data: 2017.6.21.113916 X-SEA-Spam: Gauge=IIIIIIIII, Probability=9%, Report=' HTML_70_90 0.1, HTML_NO_HTTP 0.1, LINES_OF_YELLING_3 0.05, BODYTEXTH_SIZE_3000_MORE 0, BODY_SIZE_10000_PLUS 0, DQ_S_H 0, FROM_NAME_PHRASE 0, GIF_GCT_NOTSORTED 0, GIF_PIXPERBYTE_HIGH 0, GIF_TRANSPARENCY_OFF 0, GIF_VERSION89A 0, IN_REP_TO 0, JPG_COMMON_HEADER_ORDER 0, JPG_SPAMMY_SEGMENT 0, JPG_SPAMMY_Y_RESOLUTION 0, LEGITIMATE_SIGNS 0, MSG_THREAD 0, NO_URI_HTTPS 0, REFERENCES 0, SPF_FAIL 0, WEBMAIL_SOURCE 0, WEBMAIL_USER_AGENT 0, __ANY_URI 0, __BOUNCE_NDR_SUBJ_EXEMPT 0, __CP_URI_IN_BODY 0, __CT 0, __CTYPE_HAS_BOUNDARY 0, __CTYPE_MULTIPART 0, __CTYPE_MULTIPART_ALT 0, __DQ_IP_FSO_LARGE 0, __DQ_S_HIST_1 0, __DQ_S_HIST_2 0, __DQ_S_IP_MC_100_P 0, __DQ_S_IP_MC_10_P 0, __DQ_S_IP_MC_1K_P 0, __EMBEDDED_IMG 0, __FRAUD_COMMON 0, __FRAUD_REFNUM 0, __FRAUD_REPLY 0, __GIF_ATTACHED 0, __HAS_ATTACHMENT 0, __HAS_ATTACHMENT1 0, __HAS_ATTACHMENT2 0, __HAS_FROM 0, __HAS_HTML 0, __HAS_MSGID 0, __HTML_AHREF_TAG 0, __HTML_TAG_DIV 0, __HTML_TAG_TABLE 0, __IMG_ATTACHED 0, __IN_REP_TO 0, __JPG_SPAMMY_SEGMENT_2 0, __JPG_SPAMMY_Y_RESOLUTION_3 0, __LINES_OF_YELLING 0, __MIME_HTML 0, __MIME_TEXT_H 0, __MIME_TEXT_H1 0, __MIME_TEXT_H2 0, __MIME_TEXT_P 0, __MIME_TEXT_P1 0, __MIME_TEXT_P2 0, __MIME_VERSION 0, __MSGID_32HEX 0, __MULTIPLE_URI_TEXT 0, __REFERENCES 0, __SANE_MSGID 0, __STOCK_PHRASE_24 0, __SUBJ_ALPHA_END 0, __SUBJ_ALPHA_NEGATE 0, __SXL_SIG_TIMEOUT , __SXL_URI_TIMEOUT , __TAG_EXISTS_HTML 0, __TO_MALFORMED_2 0, __TO_NAME 0, __TO_NAME_DIFF_FROM_ACC 0, __TO_REAL_NAMES 0, __URI_IN_BODY 0, __URI_NOT_IMG 0, __URI_NS , __URI_WITHOUT_PATH 0, __URI_WITH_PATH 0, __USER_AGENT 0' Return-Path: admin@prismtrial.org X-MS-Exchange-Organization-AuthSource: RL1VMEXC02.live.TRUST.XBLT.NHS.UK X-MS-Exchange-Organization-AuthAs: Anonymous DLT)/CN=RECIPIENTS/CN=PAKATS MARI-LIIS0B0EX/O=NHS NTHAMES HN/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=PAKATS MARI-LIIS0B0EXxo`GLS٥admin@prismtrial.orgSMTPEX:/O=NHS NTHAMES HN/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=PAKATS MARI-LIIS0B0EX:/O=NHS NTHAMES HN/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=PAKATS MARI-LIIS0B0Pakats, Mari-Liisܧ@B+//O=NHS NTHAMES HN/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=PAKATS MARI-LIIS0B0PRISM Trial Team+nTPRISM Trial TeamSMTPadmin@prismtrial.orgPakats, Mari-Liisܧ@B+//O=NHS NTHAMES HN/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=PAKATS MARI-LIIS0B0SMTP:ADMIN@PRISMTRIAL.ORG40|Ķ~mari-liis.pakats@bartshealth.nhs.ukIPM.Note@0P0J@0P0JrcSt 4yOp&__substg1.0_00020102*@__substg1.0_00030102*\^@__substg1.0_00040102*c__substg1.0_101C0102*__substg1.0_10060102*]a__substg1.0_10190102*e___substg1.0_10160102*f__substg1.0_10010102*__substg1.0_10120102*__substg1.0_10140102*dbm__substg1.0_10150102*l,<K 6@9%x;K ?K @$AnK B"CK D$QmK RmK W X Yd e*plI qK uvwx}:/ nK  " K    *@J~ #/yK 4( *FFKK t5d9vBv 0K 0 K 0?? ?$?K ?"?nK ?@@@@0@*1@*]*]*eeK eK eK *D  7vlI = H( 1498045783594a5d5723166775708810@prismtrial.orgimage/gifblocked.gifblocked.gif.gifGIF89ad2!,d2Mڋ޼H扦ʶ L ĢL*̦ JԪjܮ l+;blocked.gif!D7 7 4yE  0@0c~@0c~7vK 7 7777`7 1498045783594a5d57226bd053206895@prismtrial.orgimage/jpegimage001.jpgimage001.jpg.jpgJFIF``C    $ &%# #"(-90(*6+"#2D26;=@@@&0FKE>J9?@=C  =)#)==================================================>>" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?cYhX@8$7A]iM}ĿՕOӌ[By^Z~Vj3Qu\vR?ߧ1?\*I#/ JxU&ۻQ =Dѽ;춐Q*P~*PR1.7/^͂Hd2vaRV)5}~DSrJ*urp gLgNQF0sS&xȗ6gj]R%QG5H­V1L8kqên{1* N=_ݬsۮeH 6f#}x*[S{Te3]cUrMgx:a+?>ra(>4A-i {WRTq\IXT^WTyaw+; DB;1 )GOƫ\BqZNVSnrWVaVW2zQaK6*vM r=Mxu9O7t6qC/76*|l%ʰdHZ}..Yu[rG+cy:|IS 0 C eqP]ActRį؎1<# L kܩ(FeT#)M.(LP2#zqKq F#d$TvK6 ':_iաw WiC%mVr˙s$6k7v:nDrzcCE!!0WV|'!ncBxER/j׿*{|KVG Έ1=Sj0UQXxM